Under the terms of the agreement, Xiel, a specialist distributor of Nuclear Medicine, Radiotherapy and Diagnostic Radiology technologies across the U.K. and Ireland will be the exclusive commercial distributor of Illuccix in the U.K. (a top 5 European market by GDP) and the Republic of Ireland for a period of three years from the national approval date.

Xiel Managing Director, Jack Knight stated, "PSMA PET imaging is emerging as the standard of care having recently been included in European¹ and U.S.^2,3 clinical practice guidelines. We are delighted to be adding Illuccix^® to our nuclear medicine portfolio and look forward to bringing this product to British and Irish men in need, upon regulatory approval. This commercial partnership with Telix will enable us to open the door to state-of-the-art PSMA imaging for the 61,000 men diagnosed with prostate cancer each year in the U.K. and the Republic of Ireland." 

Telix CEO EMEA, Richard Valeix added, "The U.K. and Republic of Ireland are one of Telix's largest potential markets within the EMEA region, so we are pleased to have secured this agreement in anticipation of regulatory approval. Telix is creating a network of leading distribution partners to ensure we have a strong footprint to optimise our service to customer sites and ensure we can bring our imaging agent to patients across the region."

Xiel replaces Curium as Telix's exclusive distribution partner in the U.K. and the Republic of Ireland.